The rise of copyright’s blockbuster initially sparked a surge for pharma, nevertheless recent shifts present a murky picture for shareholders. Generic versions are reducing earnings, and continued litigation add https://murraydlar829462.pages10.com/the-blue-pill-and-pharma-a-precarious-play-76593422